Fifty 1 Labs, Inc. (OTC: FITY) and UAV Corp (OTC: UMAV) have announced the successful completion of the REVIVE Adaptive Platform Trial (NCT06128967), a landmark Phase III study recognized as the largest Long COVID trial to date. This randomized, double-blind trial, conducted in collaboration with global partners and prestigious institutions such as Stanford and Duke, enrolled over 600 participants and demonstrated a significant treatment benefit using repurposed medicines. The trial, powered by FITY's proprietary AI platform, not only advances the field of drug repurposing and personalized medicine but also aligns with the company's strategy to dominate the $320.6 billion functional medicine market and pursue strategic acquisitions.
The implications of this trial are profound, offering hope to millions suffering from Long COVID worldwide. By leveraging repurposed medicines, the study opens new avenues for affordable and accessible treatments, potentially reducing the global burden of Long COVID. Furthermore, the success of the REVIVE trial underscores the potential of AI in accelerating drug discovery and personalized medicine, heralding a new era in healthcare innovation.
For more details on the REVIVE trial and its findings, visit https://ibn.fm/Vq9L8.
